|
WO2017048789A1
(en)
|
2015-09-14 |
2017-03-23 |
The Board Of Regents Of The University Of Texas System |
Lipocationic dendrimers and uses thereof
|
|
RU2019126483A
(ru)
|
2017-01-23 |
2021-02-24 |
Ридженерон Фармасьютикалз, Инк. |
Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
|
|
KR20190139869A
(ko)
|
2017-04-11 |
2019-12-18 |
리제너론 파마슈티칼스 인코포레이티드 |
하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
|
|
KR20200033259A
(ko)
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
|
|
CN110891420B
(zh)
|
2017-07-31 |
2022-06-03 |
瑞泽恩制药公司 |
Cas转基因小鼠胚胎干细胞和小鼠及其应用
|
|
US20190098879A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
|
|
AU2018348195B2
(en)
|
2017-10-11 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
|
|
EP3592140A1
(en)
|
2018-03-19 |
2020-01-15 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
AU2019239971B2
(en)
|
2018-03-21 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
|
|
WO2020051223A1
(en)
|
2018-09-04 |
2020-03-12 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for organ specific delivery of nucleic acids
|
|
US12357580B2
(en)
|
2018-06-19 |
2025-07-15 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
EP3846857A4
(en)
|
2018-09-04 |
2022-10-12 |
The Board Of Regents Of The University Of Texas System |
COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS
|
|
AU2019360270B2
(en)
|
2018-10-18 |
2025-08-07 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor IX.
|
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
MX2021015122A
(es)
|
2019-06-07 |
2022-04-06 |
Regeneron Pharma |
Animales no humanos que comprenden un locus de albumina humanizado.
|
|
CN113906134B
(zh)
|
2019-06-14 |
2025-06-24 |
瑞泽恩制药公司 |
Tau蛋白病模型
|
|
KR20220044816A
(ko)
*
|
2019-08-12 |
2022-04-11 |
인티그레이티드 나노테라퓨틱스 아이엔씨. |
하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
CN111467321A
(zh)
*
|
2020-03-26 |
2020-07-31 |
深圳市新合生物医疗科技有限公司 |
一种mRNA核酸类药物胞内递送系统、制备方法和应用
|
|
US20240293317A1
(en)
*
|
2020-04-20 |
2024-09-05 |
Board Of Regents, The University Of Texas System |
Lipid nanoparticle (lnp) delivery systems and uses thereof
|
|
GB202008821D0
(en)
*
|
2020-06-10 |
2020-07-22 |
Highersteaks Ltd |
Systems and methods for cell conversion
|
|
WO2022011156A1
(en)
*
|
2020-07-10 |
2022-01-13 |
Genevant Sciences Gmbh |
Lipid nanoparticles for delivering therapeutics to lungs
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
JP2024511463A
(ja)
|
2021-03-22 |
2024-03-13 |
リコード セラピューティクス，インク． |
細胞への標的送達のための組成物および方法
|
|
CA3213107A1
(en)
|
2021-03-23 |
2022-09-29 |
Mirko HENNIG |
Polynucleotide compositions, related formulations, and methods of use thereof
|
|
CA3214023A1
(en)
*
|
2021-04-02 |
2022-10-06 |
Poulami TALUKDER |
Dendritic architectures as nonviral vectors in gene delivery
|
|
WO2022218295A1
(en)
|
2021-04-13 |
2022-10-20 |
Chengdu Westgene Biopharm Co., Ltd |
Ionizable lipids and compositions for nucleic acid delivery
|
|
CN113637708B
(zh)
*
|
2021-08-09 |
2023-07-25 |
中国科学院过程工程研究所 |
一种CRISPR-cas9基因编辑系统递送载体及其制备方法和应用
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
KR20240117571A
(ko)
|
2021-12-08 |
2024-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
돌연변이 마이오실린 질환 모델 및 이의 용도
|
|
EP4452928A1
(en)
|
2021-12-23 |
2024-10-30 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
IL313876A
(en)
*
|
2021-12-27 |
2024-08-01 |
Univ Texas |
Compositions and methods for targeted delivery to cells
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023184038A1
(en)
|
2022-04-01 |
2023-10-05 |
Nanovation Therapeutics Inc. |
Mrna delivery method and composition thereof
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
JP2025535237A
(ja)
*
|
2022-10-25 |
2025-10-24 |
ナノベーション・セラピューティクス・インコーポレイテッド |
アンチセンスオリゴヌクレオチド送達のための脂質ナノ粒子製剤
|
|
WO2024112775A1
(en)
*
|
2022-11-25 |
2024-05-30 |
Beam Therapeutics Inc. |
Compositions and methods for editing a transthyretin gene
|
|
EP4630057A1
(en)
|
2022-12-08 |
2025-10-15 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
CN119343153A
(zh)
*
|
2022-12-27 |
2025-01-21 |
北京炫景瑞医药科技有限公司 |
一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
|
|
WO2024183821A1
(zh)
*
|
2023-03-09 |
2024-09-12 |
上海吉量医药工程有限公司 |
可离子化脂质分子及其制备方法和应用
|
|
AU2024234874A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
AU2024236558A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
CN116271105B
(zh)
*
|
2023-05-18 |
2023-08-25 |
上海贝斯昂科生物科技有限公司 |
一种适于rpe细胞转染的脂质纳米颗粒及其应用
|
|
AU2024279278A1
(en)
*
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
AU2024357861A1
(en)
|
2023-10-12 |
2026-04-23 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
US12599560B2
(en)
|
2023-11-02 |
2026-04-14 |
Longuide Biopharma Corporation |
Lipids and lipid nanoparticle formulations
|
|
CN121219273A
(zh)
*
|
2023-11-02 |
2025-12-26 |
深圳厚存纳米药业有限公司 |
脂质和脂质纳米颗粒制剂
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|